To redesign nature's solutions to safely treat more diseases.
Genome editing with CRISPR-Cas nucleases has introduced new therapeutic modalities to treat a wide range of diseases.
Existing nucleases are not specific enough and can cause off-target editing (i.e., edit the genome in areas not intended), hampering its widespread use in therapeutic applications.
By augmenting and redesigning the nucleases created by nature, Evozyne is developing a comprehensive library of highly specific Cas nucleases that can access most of the genome. This combination of accessibility and specificity will allow previously untreatable diseases to be cured safely and effectively with our enzymes.